Can vilazodone (Viibryd) cause or worsen restless legs syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Vilazodone and Restless Legs Syndrome

Yes, vilazodone can cause restless legs syndrome (RLS), and this is a documented adverse effect that should prompt consideration of medication discontinuation or switching to an alternative antidepressant.

Evidence from FDA Drug Label

The FDA-approved prescribing information for VIIBRYD (vilazodone) explicitly lists restlessness as an adverse reaction associated with overdose 1. While the label doesn't specifically list RLS as a common side effect in therapeutic dosing, restlessness is a recognized manifestation that can present as or evolve into RLS symptoms [@11,1].

Research Evidence on Vilazodone and Sleep Disorders

A comprehensive analysis of 77,391 patient reviews across 32 antidepressants found that vilazodone was associated with dramatically increased probability of developing RLS compared to other antidepressants 2. Specifically:

  • Vilazodone heavily increased the probability of developing 5 out of 6 studied drug-induced sleep disorders (DISD), with proportional reporting ratios (PRR) ranging from 3.3 to 19.3 2
  • This places vilazodone among the highest-risk antidepressants for causing RLS, alongside mirtazapine, venlafaxine, and tricyclic antidepressants [@14@]

In contrast, bupropion and citalopram showed lower probabilities for developing RLS (PRR 0.2 to 0.7) [@14@], making them safer alternatives if antidepressant therapy is still needed.

Clinical Reasoning

The mechanism by which vilazodone causes RLS likely relates to its serotonergic activity. As a selective serotonin reuptake inhibitor (SSRI) with 5-HT1A partial agonist properties, vilazodone enhances serotonergic neurotransmission [@12@]. Other SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs) are well-documented RLS triggers [@17@], and vilazodone appears to carry particularly high risk within this class.

Management Algorithm

If a patient on vilazodone develops RLS symptoms:

  1. Confirm RLS diagnosis - Look for the four cardinal features:

    • Urge to move legs with uncomfortable sensations
    • Symptoms worse at rest/inactivity
    • Relief with movement
    • Symptoms worse in evening/night
  2. Check iron status immediately - Measure ferritin and transferrin saturation before making treatment changes, as iron deficiency can coexist and is treatable [@1,3]

  3. Discontinue or switch vilazodone - Given the strong association and high PRR, continuing vilazodone while treating RLS separately is not recommended

  4. Switch to lower-risk antidepressant - Consider bupropion or citalopram, which have demonstrated lower RLS risk 2

  5. If RLS persists after discontinuation, treat according to 2025 AASM guidelines:

    • First-line: Gabapentin, gabapentin enacarbil, or pregabalin (strong recommendation) 3
    • First-line: IV ferric carboxymaltose if iron parameters are appropriate (strong recommendation) 3
    • Avoid dopamine agonists as standard treatment due to augmentation risk [@1,@2,3]

Important Caveats

  • Do not abruptly stop vilazodone - Taper gradually to avoid discontinuation syndrome, which can include irritability, dizziness, and other neurological symptoms 1
  • The web-based data showing vilazodone's high RLS risk should be interpreted cautiously but aligns with known SSRI effects 2
  • Some patients may experience RLS improvement simply from vilazodone discontinuation without needing specific RLS treatment 4

Bottom line: Vilazodone carries substantial risk for causing or worsening RLS. Switch to bupropion or citalopram for continued antidepressant therapy while addressing any underlying iron deficiency.

References

Guideline

treatment of restless legs syndrome and periodic limb movement disorder: an american academy of sleep medicine clinical practice guideline.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2025

Research

Potential Effect of Vortioxetine on Restless Leg Syndrome.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.